Lyell Immunopharma, Inc. 8-K Filing
Ticker: LYEL · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lyell Immunopharma, Inc. (ticker: LYEL) to the SEC on Dec 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share LYEL Nasdaq Glo).
How long is this filing?
Lyell Immunopharma, Inc.'s 8-K filing is 2 pages with approximately 690 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 14.8 · Accepted 2025-12-05 16:05:12
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL Nasdaq Glo
Filing Documents
- d13123d8k.htm (8-K) — 30KB
- d13123dex31.htm (EX-3.1) — 182KB
- 0001193125-25-309621.txt ( ) — 365KB
- lyel-20251203.xsd (EX-101.SCH) — 3KB
- lyel-20251203_lab.xml (EX-101.LAB) — 18KB
- lyel-20251203_pre.xml (EX-101.PRE) — 11KB
- d13123d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amended and Restated Bylaws of Lyell Immunopharma, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date:December 5, 2025 By: /s/ Mark Meltz Mark Meltz General Counsel and Corporate Secretary